Disclosure of shareholdings in accordance with Art. 20 SESTA (available in English only)

November 09, 2006 02:00 ET | Source: Santhera Pharmaceuticals Holding AG

For release content, please refer to the attachment.

Recommended Reading

October 23, 2026 01:00 ET | Source: Santhera Pharmaceuticals Holding AG

Santhera’s Licensing Partner, Nxera Pharma, Submits Marketing Authorization Application for AGAMREE® (Vamorolone) in South Korea

Pratteln, Switzerland, October 23, 2026 – Santhera Pharmaceuticals (SIX: SANN) today notes that its licensing partner Nxera Pharma Co., Ltd. (“Nxera”) has submitted a Marketing Authorization...
Read More
September 30, 2026 01:00 ET | Source: Santhera Pharmaceuticals Holding AG

Santhera Pharmaceuticals Half Year Results for the six months ending 30 June 2026

Half Year Results for the six months ending 30 June 2026 with strong momentum and expanding global access position AGAMREE® for continued growth
Read More